Aerosolized Versus Intravenous Colistin-based Antimicrobial Regimens in Hospitalized COVID-19 Patients With Bacterial Coinfection: A Randomized Controlled Trial

• Status: Completed
• Trial end date: 2021-12-12
• Target enrollment: 0
• Participant gender: All

Summary

Secondary bacterial pathogen infection has been demonstrated to aggravate COVID-19 clinical outcomes. Bacterial infections acquired during a hospital stay are likely resistant to several antimicrobial medicines, making COVID-19 patient management difficult. As a result, it is believed that aerosolized colistin might be a viable choice for treating secondary bacterial infections caused by gram-negative resistant strains in individuals who also have COVID-19 infection.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beni-Suef University
• Treatments: Colistin

Criteria

Inclusion Criteria:

• Covid-19 patients with secondary gram-negative bacterial infections

Exclusion Criteria:

• Patients with resistant bacterial strains to polymyxins

• patients less than 18 years